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Abstract
Introduction: Young age at the time of diagnosis of breast cancer is an independent factor of poor prognosis. In
many treatment guidelines, the recommendation is to treat young patients with adjuvant chemotherapy regardless
of tumor characteristics. However, limited data on prognostic factors are available for young breast cancer patients.
The purpose of this study was to determine the prognostic value of established clinical and pathological
prognostic factors in young breast cancer patients.
Methods: Data from four European Organisation for Research and Treatment of Cancer (EORTC) clinical trials were
pooled, resulting in a dataset consisting of 9,938 early breast cancer patients with a median follow-up of 11 years.
For 549 patients aged less than 40 years at the time of diagnosis, including 341 node negative patients who did
not receive chemotherapy, paraffin tumor blocks were processed for immunohistochemistry using a tissue
microarray. Cox proportional hazard analysis was applied to assess the association of clinical and pathological
factors with overall and distant metastasis free survival.
Results: For young patients, tumor size (P = 0.01), nodal status (P = 0.006) and molecular subtype (P = 0.02) were
independent prognostic factors for overall survival. In the node negative subgroup, only molecular subtype was a
prognostic factor for overall survival (P = 0.02). Young node negative patients bearing luminal A tumors had an
overall survival rate of 94% at 10 years’ follow-up compared to 72% for patients with basal-type tumors.
Conclusions: Molecular subtype is a strong independent prognostic factor in breast cancer patients younger than
40 years of age. These data support the use of established prognostic factors as a diagnostic tool to assess disease
outcome and to plan systemic treatment strategies in young breast cancer patients.
Introduction
The incidence of early stage breast cancer in young
women is increasing. At present, breast cancer at a
young age, that is, less than 40 years, accounts for
approximately 5 to 7.5% of the total number of cases
diagnosed each year in Western Europe and the US
[1-3]. Based upon multiple retrospective analyses that
demonstrated the unfavorable impact of young age on
prognosis in breast cancer, several current consensus
guidelines have included age ≥ 35 years as an absolute
indication for adjuvant systemic chemotherapy irrespec-
tive of other tumor characteristics [4-6]. These guide-
lines imply that for young patients with favorable tumor
features such as small tumor size and negative axillary
nodal status, adjuvant chemotherapy and hormonal
therapy for patients with hormone receptor positive
tumors is advised although absolute treatment benefits
are not well known. Moreover, the long-term toxicity of
adjuvant chemotherapy and the implications of possible
fertility impairment and premature menopause are of
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an increased risk of developing distant metastases, local
recurrence rates after mastectomy or breast conserving
therapy are also higher than in older patients [5]. It has
been demonstrated that an additional boost dose of
radiotherapy after breast-conserving surgery decreases
the risk of local recurrence especially in young women
[8], but these loco-regional recurrence rates are still sig-
nificantly higher compared with mastectomy in the
young patients.
Retrospective analyses have demonstrated breast can-
cer at a very young age to be associated with higher
grade, estrogen receptor negative tumors, a more
advanced stage of disease at the time of diagnosis, and
t h ep r e s e n c eo fB R C A - 1o r- 2g e r m l i n em u t a t i o n s
[9-13]. Recent gene expression profiling studies showed
that tumors of young women showed a higher probabil-
ity of PI3K, Myc, and b-catenin deregulation and lower
mRNA levels of estrogen receptor-a, estrogen receptor-
b and progesterone receptor, but higher levels of HER2,
and epidermal growth factor receptor [14,15].
More refined knowledge of prognostic factors in young
breast cancer patients will be of use in guiding therapy,
including adjuvant chemotherapy, in these women. The
prognostic value of molecular subtype based on immuno-
histochemistry is uncertain within the group of young
breast cancer patients. Therefore, we pooled the data of
four randomized European Organisation for Research
and Treatment of Cancer (EORTC) early stage breast
cancer trials and collected and characterized tumor mate-
rial of patients younger than 40 years in order to perform
multivariate prognostic factor analyses.
Materials and methods
T h ed a t au s e di nt h i ss t u d yw e r eo b t a i n e df r o mf o u r
randomized phase III EORTC clinical trials that
included patients with early stage breast cancer. The
trials randomized between two types of loco-regional
therapy and between different timing of the same type
of systemic therapy. The detailed features of these trials
have been described in detail previously [16-19]. The
trial protocols are summarized below:
EORTC trial 10801 (1980 to 1986, median follow-up
13.4 years) was conducted in order to assess the safety
of breast conserving treatment. Patients were rando-
mized between breast conserving surgery combined with
radiotherapy and modified radical mastectomy. Six
cycles of adjuvant chemotherapy with cyclophosphamide
100 mg/m
2 given orally on days 1 to 14, methotrexate
40 mg/m
2 given intravenously on Days 1 and 8, and 5-
fluorouracil 600 mg/m
2 (CMF) given intravenously on
Days 1 and 8, were indicated for all node-positive
patients under the age of 55. No information was col-
lected on hormonal therapy. A total number of 902
patients were randomized of which 113 patients aged
less than 40 years at the time of diagnosis [16].
EORTC trial 10854 (1986 to 1991, median follow-up
10.8 years) studied the question of whether one course
of peri-operative chemotherapy given directly after sur-
gery yields better results in terms of treatment outcome
than surgery alone. Peri-operative chemotherapy con-
sisted of one single course of doxorubicin 50 mg/m
2,5 -
fluorouracil 600 mg/m
2, and cyclophosphamide 600 mg/
m
2 (FAC), administered intravenously within 36 hours
after surgery. Node-positive premenopausal patients in
the peri-operative chemotherapy group were recom-
mended to receive an additional five cycles of CMF.
Node-positive premenopausal patients in the surgery
alone group were advised to receive one conventional
course of FAC followed by five cycles of CMF. Pro-
longed adjuvant systemic treatment was left to the dis-
cretion of the local investigators. A total number of
2,795 patients were included of which 396 patients aged
less than 40 years at time of diagnosis [17].
EORTC trial 10902 (1991 to 1999, median follow-up
10 years) was set up to compare pre-operative adjuvant
chemotherapy with postoperative chemotherapy. Che-
motherapy consisted of four cycles of 5-fluorouracil 600
mg/m
2,e p i r u b i c i n6 0m g / m
2, and cyclophosphamide
600 mg/m
2 (FEC) administered intravenously, at three-
weekly intervals. A total number of 698 patients were
randomized of which 125 patients aged less than 40
years at time of diagnosis [18,20].
EORTC trial 22881 (1989 to 1996, median follow-up
10.8 years) studied the value of a boost dose after pri-
mary breast conserving surgery. Patients with stage I or
II breast cancer who had undergone microscopically
complete surgical removal of the tumor and axillary dis-
section were randomly assigned to undergo 50-Gy irra-
diation of the whole breast with or without an
additional dose of 16 Gy to the tumor bed. Patients with
a microscopically incomplete excision were assigned to
receive booster doses of 10 or 26 Gy. Patients with axil-
lary lymph node involvement received adjuvant systemic
therapy: premenopausal patients received chemotherapy
(CMF, FEC, or FAC), and postmenopausal patients
received tamoxifen. A total number of 5,569 patients
were randomized of which 558 patients aged less than
40 years at time of diagnosis [8,19].
Adjuvant hormonal therapy for premenopausal hor-
mone receptor positive patients was not yet recom-
mended at the time these trials were conducted. In the
oldest two trials, tamoxifen administration was not even
recorded. In the trials where tamoxifen use was
recorded, less than 5% of patients ≥ 40 years received
tamoxifen. Therefore, we assumed that only a very small
fraction of the young patients in these studies received
tamoxifen.
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Page 2 of 11Collection of tumor material and immunohistochemistry
A request was sent to participating institutions to sub-
mit paraffin blocks containing a representative part of
the tumor from all patients aged less than 40 years at
the time of diagnosis except for those who had partici-
pated in EORTC trial 10902 and received neoadjuvant
chemotherapy (this group of patients was excluded for
this study to avoid the influence of down-staging by pre-
operative chemotherapy). Tumor tissue was collected
and processed for immunohistochemistry using a tissue
microarray. Three core biopsies of 0.6 mm were taken
from every tumor specimen and placed in a so-called
donor block. This procedure has been described pre-
viously [21-24]. A representative standard histological
section from each individual tumor was stained with
H&E to assess tumor type, to perform histological grad-
ing according to Elston and Ellis, and to assess the pre-
sence and extent of lymphangio invasion (none versus
one to five versus more than five vessels) [25]. ER, PgR,
HER2 and P53 expression levels were assessed using
immunohistochemistry. Detailed procedures have been
described previously [26-28]. In summary, a tissue
microarray slide was stained and scored counting the
percentage of positive cells and taking the mean value
of the three tumor biopsies. For estrogen receptor
expression, tumors with > 1% of the tumor cells show-
ing nuclear staining were considered positive. For pro-
gesterone receptor expression, tumors with > 10% of the
tumor cells showing nuclear staining were considered
positive. For P53 accumulation, a semi-quantitative sys-
t e mw a su s e db a s e do nt h es u mo ft h em e a ns t a i n i n g
intensity (0 to 3; none to strong) and an estimation of
the percentage of positive cell nuclei (0 to 4; 0% to >
75%); this allowed a sum score of 0 to 7, with staining ≥
4 being considered positive [26,27]. HER2 expression
was scored estimating the level of membranous staining
( 0 ,1 + ,2 + ,o r3 + ) .S t r o n gm e m b r a n o u ss t a i n i n gi n>
30% of tumor cells (3+) was considered positive. The
molecular breast cancer subtypes were approximated
using histological grade and the ER, PgR, and HER2 sta-
tus of the primary tumor. Patients were categorized as
follows: luminal A (ER+ or PgR+ and HER-2- and grade
1 or 2), luminal B (ER+ or PgR+ and HER-2+; or ER+
or PgR+ and HER2- and grade 3), HER-2 (ER- and PgR-
and HER-2+), and basal type (ER- and PgR- and HER-2-
). Estimations of tumor grade and protein expression
levels were scored by two investigators (MJV and JAH)
simultaneously who had to come to an agreement in
case of different views.
Statistical analyses
Data analysis was performed at the Leiden University
Medical Center using SPSS for Mac (version 18.0; SPSS,
Chicago, IL, USA). The Chi-square test was used to
compare the distribution of baseline characteristics
among groups. Endpoints studied were overall survival
and distant metastasis free survival. Overall survival
time was defined as the time between randomization
and death from any cause. Distant metastasis-free survi-
val time was defined as time to distant metastasis or
death if the latter event occurred before a distant metas-
tasis was diagnosed. Survival analyses were performed
using the Kaplan Meier method. Covariates included,
patient age, and tumor- and treatment related character-
istics. Tumor characteristics were tumor size, nodal sta-
tus, histological grade, hormone receptor status, HER2
status, P53 status, molecular subtype and lymphangio
invasion. Treatment characteristics were type of surgery
and administration of chemotherapy. Tamoxifen use
was not included because of the high rate of missing
data for this variable. Cox proportional hazard regres-
sion models were used to estimate hazard ratios (HR)
with 95% confidence intervals (CI). A multivariate Cox
regression model was fitted th a tw a sb a s e do na l lc h a r -
acteristics that had a P-value up to .10 in the univariate
analysis. Variables determining molecular subtype were
not included in multivariate analyses if molecular sub-
type was included. A 5% significance level was used and
all tests are two-sided.
Results
Prognostic factors in young patients
A total of 9,938 early stage breast cancer patients parti-
cipated in the four trials. Of this dataset, 1,192 (12%)
patients were aged less than 40 years at the time of
diagnosis. Paraffin embedded tumor material was
obtained and processed into a tissue microarray for 549
patients aged less than 40 years (Table 1). Median age
of these patients was 36.8 years. Tumors were subdi-
vided according to molecular subtype: 111 patients
(24%) aged less than 40 years had triple-negative
tumors, 154 (34%) patients had luminal A tumors, 157
(34%) had luminal B tumors and 35 (8%) had HER2
tumors. Twenty-nine percent of tumors were p53 posi-
tive (Table 1). At time of analysis, 143 of 549 patients
had died and 64 patients had developed distant metas-
tases and were still alive.
At univariate analysis, pathological tumor size, nodal
status, histological grade, lymphangio invasion, proges-
terone receptor status, molecular subtype, type of sur-
gery and adjuvant chemotherapy were significantly
associated with overall and distant metastasis free survi-
val (Supplementary Table S1 in Additional file 1). HER2
and p53 status did not show an association with overall
or distant metastasis free survival and were not included
at subsequent multivariate analysis. At multivariate ana-
lysis (Table 2), pathologic tumor size, nodal status, and
molecular subtype remained the only independent
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Page 3 of 11Table 1 Characteristics of patients aged less than 40 years with immunohistochemistry results
Characteristic All patients
(N = 549)
Node negative patients (N = 341)
No. of Patients % No. of Patients %
Age, years
Median (range) 36.8 (23 to 40) 36.8 (25 to 40)
Age distribution
≥ 30 years 57 10 40 12
31 to 35 years 178 32 107 31
35 to 40 years 314 58 194 57
Pathological tumor size
T1a and T1b 37 7 30 10
T1c 296 60 241 64
T2 158 32 82 26
T3 6 1 2 1
Missing 32 26
Pathological nodal status
Negative 341 63 341 100
Positive 204 37 0 0
Missing 4
Surgery
Breast conserving 446 81 299 88
Mastectomy 102 19 42 12
Missing 1 0
Adjuvant chemotherapy
1
No 326 60 304 89
Yes 221 40 37 11
Missing 2 0
ER status
Positive 310 66 115 41
Negative 158 34 165 59
Missing 81 61
PgR status
Positive 223 48 141 51
Negative 241 52 136 49
Missing 85 64
Tumor type
Ductal 497 96 306 96
Lobular 17 3 10 3
Other 5 1 4 1
Missing 30 21
Histological grade
I7 6 1 5 5 4 1 7
II 165 32 93 29
III 276 53 172 54
Missing 32 22
Lymphangio invasion
None 357 69 243 76
1-5 vessels 86 17 49 15
> 5 vessels 76 14 27 9
Missing 30 22
HER2 status
Negative 346 74 216 63
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Page 4 of 11prognostic factors for both overall survival and distant
metastasis free survival. For distant metastasis free survi-
val, molecular subtype was a trend-significant prognostic
factor (P = 0.06; Table 2).
Prognostic factors in young node negative patients
The subgroup of node negative patients aged less than
40 years consisted of 640 patients. Of 341 patients,
tumor material was available for analysis (Table 1). Of
these node negative patients, 304 (89%) patients did not
receive adjuvant chemotherapy.
At univariate analysis, pathological tumor size, histolo-
gical grade, estrogen receptor status and molecular sub-
type were significantly associated with overall survival
and distant metastasis free survival (Supplementary
Table S2 in Additional file 1). In addition, progesterone
receptor status and the administration of adjuvant che-
motherapy were significantly associated with overall sur-
vival. Figures 1, 2 and 3 show the impact of molecular
subtype, histological grade and pathological tumor size,
respectively, on overall and distant metastasis-free survi-
val in the subgroup of node-negative patients aged less
than 40 years. Ten-year survival rates for the molecular
subtypes were 94% for luminal A, 93% for HER2, 78%
for luminal B and 72% for basal (Figure 1A). Of note,
the overall survival rate for young patients bearing a
grade I tumor was 92% at 11 years of follow-up, whereas
patients with grade III tumors had a survival rate of 72%
(Figure 2A).
At multivariate analysis (Table 3), molecular subtype
was associated with overall survival (P = 0.02; basal sub-
type versus luminal A subtype: hazard ratio (HR) 0.22,
95% CI 0.08 to 0.60, P =0 . 0 0 3 )a n dd i s t a n tm e t a s t a s i s
free survival (P = 0.08; basal subtype versus luminal A
subtype: HR 0.46, 95% CI 0.25 to 0.85, P = 0.013).
Discussion
In this study, we performed a retrospective pooled ana-
lysis to gain further insight into tumor characteristics of
young breast cancer patients. In young patients, molecu-
lar subtype was the strongest prognostic factor of the
covariates studied, distinguishing young patients with a
favorable prognosis from young patients with an unfa-
vorable prognosis.
In our study, young node negative patients with lumi-
nal A and HER2 tumors had excellent long-term overall
Table 2 Multivariate analysis for prognostic factors in
549 patients aged less than 40 years
Overall survival Distant disease-free
survival
HR 95% CI P HR 95% CI P
pT2 + pT3 1.68 1.12 to
2.52
0.01 1.61 1.14 to
2.25
0.006
pN + 2.62 1.31 to
5.23
0.006 2.21 1.24 to
3.96
0.008
Lymphangio invasion 0.75 0.73
No vessels 1 1
1 to 5 vessels 0.93 0.53 to
1.62
0.97 0.61 to
1.53
> 5 vessels 1.18 0.71 to
1.97
1.17 0.75 to
1.83
Molecular subtype 0.02 0.06
Basal 1 1
Luminal A 0.50 0.29 to
0.86
0.69 0.44 to
1.08
HER2 0.42 0.17 to
1.04
0.45 0.21 to
0.99
Luminal B 0.92 0.56 to
1.48
1.01 0.67 to
1.53
Breast conserving
therapy
0.76 0.47 to
1.24
0.27 0.81 0.53 to
1.23
0.33
Adjuvant
chemotherapy
0.68 0.35 to
1.33
0.26 0.65 0.37 to
1.13
0.13
Abbreviations: HR, hazard ratio; CI, confidence interval.
Table 1 Characteristics of patients aged less than 40 years with immunohistochemistry results (Continued)
Positive 119 26 64 19
Missing 84 61
P53 status
Negative 331 71 198 72
Positive 133 29 78 28
Missing 85 65
Molecular subtype
Luminal A 154 34 79 29
Luminal B 157 34 86 32
HER-2 35 8 90 34
Basal (triple-negative) 111 24 14 5
Missing 92 72
1 EORTC trial 10854 randomized between one course of peri-operative chemotherapy which was not considered as prolonged chemotherapy.
Abbreviations: ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PgR, progesterone receptor.
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Page 5 of 11survival rates of 94% and 93%, respectively, and distant
disease-free survival rates of 83% and 79%, respectively,
at 10-year follow-up (Figures 1A, B). Of note, only 3 out
of 86 young node negative patients with luminal A
tumors received adjuvant chemotherapy. Therefore,
these data suggest that molecular subtype can be
utilized in adjuvant treatment planning in young node
negative patients. Recently, Cancello et al. showed that
very young patients with basal, luminal B or HER2
breast cancer have a worse prognosis when compared
with older patients with similar characteristics of disease
[29].
A 
B 
Figure 1 Clinical outcome for node negative patients aged less than 40 years stratified by molecular subtype.A ,O v e r a l ls u r v i v a l .B ,
Distant disease-free survival.
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dent prognostic role of histological grade in young breast
cancer patients. Sundquist et al. showed that patients
bearing histological grade III tumors had a poor overall
survival of 41% at the 11-year follow-up in a Swedish
cohort of 107 patients aged less than 40 years [30].
Although histological grade was associated with overall
survival, it did not reach statistical significance (Grade I
versus III: HR 4.19; 95% CI 0.91 to 19.5), and nodal status
was the strongest prognostic factor. Kollias et al. demon-
strated in a cohort of 2,879 patients that the worse prog-
nosis of the age group younger than 35 years (N = 120)
A 
B 
Figure 2 Clinical outcome for node negative patients aged less than 40 years stratified by histological grade.A ,O v e r a l ls u r v i v a l .B ,
Distant disease-free survival.
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grade III breast cancers in the young group [31]. In a
recent study, high histological grade and young age were
identified as the most important risk factors for local
relapse [32]. Our study suggests that histological grade (as
part of molecular subtype) is an important prognostic fac-
tor in young breast cancer patients.
Among the established prognostic and predictive fac-
tors in young breast cancer patients, the estrogen recep-
tor status is of particular interest. Recently, we showed
 
A 
B 
Figure 3 Clinical outcome for node negative patients aged less than 40 years stratified by pathological tumor size. A, Overall survival. B,
Distant disease-free survival.
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benefit in hormone receptor positive young breast can-
cer patients [33]. The Korean Breast Cancer Society
recently reported that young age was associated with a
greater probability of death in breast cancer patients
[34]. When studied in more detail, the survival differ-
ence was only found in the hormone receptor positive
group [34]. As these data were collected from 1992
onwards, young hormone receptor positive patients
received tamoxifen, in contrast to the patients in our
study who were treated before adjuvant tamoxifen treat-
ment became a standard in a large proportion of breast
cancer patients with hormone receptor positive disease.
The authors suggested that tamoxifen therapy might
provide less survival benefit in young hormone receptor
positive breast cancer patients as compared to older
hormone receptor positive breast cancer patients. How-
ever, several trials have suggested an equal effect of
endocrine therapy as compared to chemotherapy in hor-
mone receptor positive premenopausal breast cancer
patients [35,36]. In our data set of older EORTC trials,
young hormone-receptor positive patients did not
receive hormonal therapy. Notwithstanding, in our
study, young patients with luminal A tumors had an
excellent prognosis, which might have been augmented
with the administration of hormonal therapy.
The current study has a number of limitations. First, the
study design was a retrospective analysis of four heteroge-
neous randomized trials that were not primarily designed
to test differences in outcome between young and old
patients. Second, tumor material could not be collected
for all patients aged less than 40 years and this could
introduce selection bias. However, patient and traditional
tumor characteristics were evenly distributed between the
group for which tumor blocks were available and the
group for which no tumor blocks could be collected
(Supplementary Table S3 in Additional file 1). Third,
information on tamoxifen use is largely missing. However,
in the trials in which tamoxifen use was recorded, less
than 5% of the patients younger than 40 years received
tamoxifen. Despite these limitations, the current pooled
analysis used individual patient data of four high-quality
randomized controlled trials with renewed histopathologi-
cal analysis to assess prognostic factors in young breast
cancer patients. These data provide a robust estimate of
breast cancer survival in relation to young age; and of the
value of prognostic factors in young breast cancer patients.
We believe our data justify a more critical view concerning
current adjuvant chemotherapy guidelines in young low-
risk breast cancer patients.
Conclusions
T h ee s t a b l i s h e dp r o g n o s t i cf actors molecular subtype,
(including hormone receptor status, histological grade
and HER2 receptor status), tumor size and nodal status
remain independent prognostic factors on disease out-
come in young breast cancer patients. In particular,
molecular subtype was strongly associated with overall
and distant metastasis free survival. Future treatment
guidelines concerning young breast cancer patients
should be refined based upon tumor characteristics,
probably derived from microarray driven translational
research projects, and not based upon age alone [37-39].
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